The company has raised an additional 10.6 million SEK to accelerate commercialization of its SiPore health and food supplement portfolio.
“In the current climate, the rapid completion and oversubscription of this new fund raise is a sign of confidence in both SiPor’s huge potential and our commercialization strategy. In addition to our core prediabetes market, we have identified three major areas which can bring cashflow to the company in the near future – dietary supplements, veterinary products for cats and oral health – with these funds we can now implement our plans for each,” says Sana Alajmovic, Sigrid’s Co-Founder and CEO.
Recently appointed Chairman
Both current and new investors participated including recently appointed Chairman, Mattias Ankarberg. In addition to the funds, Sigrid views Ankarberg’s vast experience from the consumer industry, most recently at retail giant H&M, as ideal to help diversify its SiPore technology into the food supplement, veterinary and oral health markets, the company states in a press release.
“Sigrid has continued to move forward at a high pace. A capsule product has been developed, the consumer pre-launch program is completed, and preparations for the world’s second largest commercial pre-diabetes study SHINE are coming to a close,” adds Mattias Ankarberg, Sigrid’s Chairman.
Photo of Sana Alajmovic: Sigrid Therapeutics